¥È¥Ã¥× º¹Ê¬ °ìÍ÷ ¥½¡¼¥¹ ¸¡º÷ ¥Ø¥ë¥× PDF RSS ¥í¥°¥¤¥ó

¹ü·ÏÅý¼À´µ¤ÎÂÛ»ù¼£ÎŤβÄǽÀ­

¹ü·ÏÅý¼À´µ¤ÎÂÛ»ù¼£ÎŤβÄǽÀ­

¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡¡Ê¼¼·î ½ß¡¡2014ǯ8·î28Æü¡Ë

¿Þ1¡¥¡¡Âè5²óÂÛ»ù¹ü·ÏÅý¼À´µ¥Õ¥©¡¼¥é¥à¡Ö¹ü·ÏÅý¼À´µ¤Î¼£ÎÅ¡ÝÂÛ»ù¼£ÎŤò»ëÌî¤Ë¤¤¤ì¤Æ¡×¡Ê2012ǯ12·î2Æü¡¤ÀçÂæ¡Ë¡¥º¸¤è¤êÃÝë·òÀèÀ¸¡ÊÅ纬Âç¡Ë¡¤ºÊÌÚÈϹÔÀèÀ¸¡ÊµþÅÔÂç¡Ë¡¤Âç±ò·Ã°ìÀèÀ¸¡ÊÂçºåÂç¡Ë¡¤ÅçÅÄδÀèÀ¸¡ÊÆüËÜ°åÂç¡Ë¡¥ ¡¡

 ¾¶Ï¿

¹ü·ÏÅý¼À´µ¤ÎÂÛ»ù¼£ÎŤȤ·¤Æ¸½ºß¹Í¤¨¤é¤ì¤Æ¤¤¤ëÊýË¡¤Ë¡¤­¡¹ÚÁÇÊä½¼ÎÅË¡¡¤­¢ºÆÀ¸°å³Ø¤È¤·¤Æ¤Î´´ºÙ˦°Ü¿¢¡¤­£°äÅÁ»Ò¼£ÎŤΣ³¤Ä¤¬¤¢¤ë¡¥¹ÚÁÇÊä½¼ÎÅË¡¤Ë¤Ä¤¤¤Æ¤Ï¡¤Äã¥Õ¥©¥¹¥Õ¥¡¥¿¡¼¥¼¾É¡ÊHPP¡Ë¤ËÂФ¹¤ë¥ê¥³¥ó¥Ó¥Ê¥ó¥ÈALPÀ½ºÞ¤Î¼£¸³¤¬¤¹¤Ç¤ËÆüËܤǤâ¤Ï¤¸¤Þ¤Ã¤Æ¤ª¤ê¡¤¤¤¤º¤ìÂÛ»ù¤Ë¤âŬ±þ¤µ¤ì¤ë¤³¤È¤¬´üÂÔ¤µ¤ì¤ë¡¥ºÆÀ¸°å³Ø¤È¤·¤Æ¤Ï¹ü·ÁÀ®ÉÔÁ´¾ÉÂÛ»ù¤Ë¤¿¤¤¤¹¤ë´ÖÍÕ·Ï´´ºÙ˦°Ü¿¢¤ÎÊó¹ð¤¬Ê£¿ô¤¢¤ê¡¤¤¤¤º¤ì¤â¤¢¤ëÄøÅ٤μ£ÎŸú²Ì¤¬Ç§¤á¤é¤ì¤Æ¤¤¤ë¡¥°äÅÁ»Ò¼£ÎŤˤ«¤ó¤·¤Æ¤Ï¡¤¹ñÆâ¤Ç¤Ê¤µ¤ì¤¿HPP¥â¥Ç¥ë¥Þ¥¦¥¹¤òÍѤ¤¤¿ÂÛ»ù¤Î°äÅÁ»Ò¼£ÎŤθ¦µæ¤Ç¡¤¤­¤ï¤á¤Æ¤¹¤°¤ì¤¿¼£ÎŸú²Ì¤òÆÀ¤¿¡¥¹ü·ÏÅý¼À´µ¤ÎÂÛ»ù¼£ÎŤϤ½¤Î°ÂÁ´À­¤ÈÎÑÍýŪ¤ÊÌäÂê¤Ë¤è¤ê¤¤¤º¤ì¤â¤Þ¤À¸¦µæÃʳ¬¤Ë¤¢¤ë¤¬¡¤½ÐÀ¸»þ¤Ë¤Ï¤¹¤Ç¤ËÉÂÂÖ¤¬´°À®¤·¤Æ¤¤¤ë¹ü·ÏÅý¼À´µ¤Î½Å¾ÉÎã¤òµßÌ¿¤·¼£ÎŤ·¤Æ¤¤¤¯¤¿¤á¤Ë¤ÏÁᤤÃʳ¬¤Ç¤Î¼£ÎŤ¬µá¤á¤é¤ì¤Æ¤ª¤ê¡¤¤³¤ì¤é¤ÎÂÛ»ù¼£ÎŤˤ¿¤¤¤¹¤ë´üÂÔ¤ÏÂ礭¤¤¡¥

¡¡

 ¤Ï¤¸¤á¤Ë

¡ÖÂÛ»ù¹ü·ÏÅý¼À´µ¥Õ¥©¡¼¥é¥à¡×(1)¤Ï¡¤»º²Ê°å¡¤¾®»ù²Ê°å¡¤¾®»ùÀ°·Á³°²Ê°å¡¤¾®»ùÊü¼ÍÀþ²Ê°å¤Ê¤É¤ÎÎ×¾²°å¤È¡¤°äÅÁ»Ò¤äȯÀ¸¤Ê¤É¤ò°·¤¦´ðÁ÷ϸ¦µæ¼Ô¤Ê¤É¤¬¡¤¼«¼çŪ¤Ë½¸¤Þ¤Ã¤Æ¤Ç¤­¤¿non-official¤Ê¥Í¥Ã¥È¥ï¡¼¥¯¤Ç¤¢¤ë¡¥½ÐÀ¸Á°¤«¤é½ÐÀ¸¸å¤Î¼þ»º´ü¤Ë¤ª¤±¤ë¹ü·ÏÅý¼À´µ¤Î»ù¤Î¿ÇÃǼ£ÎÅ¡¤¤¢¤ë¤¤¤Ï¿·¤·¤¤Ãθ«¤Ë¤Ä¤¤¤Æ¸¡Æ¤¤ä¾ðÊó¸ò´¹¤ò¤ª¤³¤Ê¤¤¡¤¸Ä¡¹¤Î·Ð¸³¤ä¥Î¥¦¥Ï¥¦¤ò¶¦Í­¤¹¤ë¤³¤È¤Ë¤è¤Ã¤Æ¤³¤ì¤«¤é¤Î¼þ»º´üÎ×¾²¤ËÀ¸¤«¤·¤Æ¤¤¤¯¤³¤È¤òÌÜŪ¤È¤¹¤ë¡¥¤Þ¤¿¡¤°ìÈ̤ΰåÎÅ»ÜÀߤ«¤é¤Î¥³¥ó¥µ¥ë¥È¤µ¤ì¤¿¾ÉÎã¤Ë¤Ä¤¤¤Æ½õ¸À¤ä¥µ¥Ý¡¼¥È¤Ê¤É¤â¤ª¤³¤Ê¤Ã¤Æ¤¤¤ë¡¥

¸½ºß¡¤Ç¥¿±´ÉÍý¤Ç¤ÏĶ²»Çȸ¡ºº¤¬°ìÈ̲½¤·¡¤ÂÛ»ù·×¬¤Î¤Ê¤«¤ÎÂçÂܹüŤÎû½Ì¤ò·Àµ¡¤È¤·¤Æ¡¤ÂÛ»ù¹ü·ÏÅý¼À´µ¾ÉÎ㤬¤ß¤Ä¤«¤Ã¤Æ¾Ò²ð¤µ¤ì¤Æ¤¯¤ë¤³¤È¤¬Â¿¤¯¤Ê¤Ã¤¿¡¥¤³¤ì¤é¤Î¼À´µ¤Ï¡¤½Ð»ºÁ°¸å¤ä¿·À¸»ùÁá´ü¤Ë»àË´¤Ë»ê¤ë¤â¤Î¤«¤é¡¤À¸Ì¿Í½¸åÎɹ¥¤Î¤â¤Î¤Þ¤ÇÈó¾ï¤Ë¿´ô¤Ë¤ï¤¿¤ë¡¥¤â¤Á¤í¤óÀ¸Ì¿Í½¸åÉÔÎɤΰ췲¤Ë¤¿¤¤¤·¤Æ¤Ï¼þ»º´ü´ÉÍý¤Ë¶ìθ¤¹¤ë¤³¤È¤¬Â¿¤¯¡¤Àµ³Î¤Ê¿ÇÃǤˤâ¤È¤Å¤¤¤¿ÂÛ»ù´ü¤«¤é¤Î¼£ÎŤä´ÉÍý¤¬µá¤á¤é¤ì¤Æ¤¤¤ë¡¥

2012ǯǯ12·î¤ËÀçÂæ¤Ç³«ºÅ¤µ¤ì¤¿Âè10²óÆüËÜÂÛ»ù¼£Îųزñ¤Î3ÆüÌܤˤϡ¤¥¸¥ç¥¤¥ó¥È´ë²è¤È¤·¤ÆÂè5²óÂÛ»ù¹ü·ÏÅý¼À´µ¥Õ¥©¡¼¥é¥à¡Ö¹ü·ÏÅý¼À´µ¤Î¼£ÎÅ¡ÝÂÛ»ù¼£ÎŤò»ëÌî¤Ë¤¤¤ì¤Æ¡×¤¬¤ª¤³¤Ê¤ï¤ì¤¿¡Ê¿Þ1¡Ë¡¥¥×¥í¥°¥é¥à¤Ï¡¤ÃÝë·ò¡ÊÅ纬Âç³ØÍ¢·ìÉô·ó¾®»ù²Ê¡Ë¡Ö½Å¾ÉÄã¥Õ¥©¥¹¥Õ¥¡¥¿¡¼¥¼¾É¤ËÂФ¹¤ë¹ü¿ñ°Ü¿¢Ê»ÍÑƱ¼ï´ÖÍÕ·Ï´´ºÙ˦°Ü¿¢¡×¡¤ºÊÌÚÈϹԡʵþÅÔÂç³ØiPSºÙ˦¸¦µæ½ê¡Ë¡ÖºÙ˦¥ê¥×¥í¥°¥é¥ß¥ó¥°µ»½Ñ¤òÍѤ¤¤¿Æð¹ü¼À´µ¥â¥Ç¥ê¥ó¥°¡×¡¤Âç±ò·Ã°ì¡ÊÂçºåÂç³Ø¾®»ù²Ê¡Ë¡Ö¹ü·ÏÅý¼À´µ¤Î¿·¤¿¤Ê¼£ÎÅË¡¡×¡¤ÅçÅÄδ¡ÊÆüËÜ°å²ÊÂç³Øʬ»Ò°äÅÁ³Ø¡Ë¡ÖÄã¥Õ¥©¥¹¥Õ¥¡¥¿¡¼¥¼¾É¤Î°äÅÁ»Ò¼£ÎšפȤ¤¤¦£´¤Ä¤ÎÆÃÊֱ̹é¤Ç¤¢¤Ã¤¿¡¥ËܹƤϤ³¤³¤ÇµÄÏÀ¤µ¤ì¤¿¹ü·ÏÅý¼À´µ¤ÎÂÛ»ù¼£ÎŤβÄǽÀ­¤ò¤â¤È¤Ë¤Þ¤È¤á¤é¤ì¤¿¡¥

¡¡

 ¤Ê¤¼ÂÛ»ù¼£ÎŤʤΤ«¡©

¹ü·ÏÅý¼À´µ¤Î¤«¤«¤¨¤ëÌäÂê¤Î³Ë¿´¤Ï¡¤¤Û¤È¤ó¤É¤¹¤Ù¤Æ¤Î¹ü·ÏÅý¼À´µ¤¬¼£ÎŤǤ­¤Ê¤¤¤³¤È¤Ë¤¢¤ë¡¥¤ï¤ì¤ï¤ì¤Î½ÐÀ¸Á°¿ÇÃǤλî¤ß¤â¡¤ÂÛ»ù´ü¤Ë¿ÇÃǤ¹¤ë¤³¤È¤Ë¤è¤ê¿Í¹©Ç¥¿±ÃæÀä¤ò¤ª¤³¤Ê¤¦ÌÜŪ¤È¸í²ò¤µ¤ì¤ë¤³¤È¤¬¤¢¤ë¡¥¤â¤·¹ü·ÏÅý¼À´µ¤¬¼£ÎŲÄǽ¤È¤Ê¤ì¤Ð½ÐÀ¸Á°¿ÇÃǤˤĤ¤¤Æ¤Î¹Í¤¨¤«¤¿¤ä¼è¤ê¤¯¤ß¤Ï¤ª¤ª¤­¤¯ÊѤï¤Ã¤Æ¤¤¤¯¤À¤í¤¦¡¥À¸Ì¿Í½¸å¤¬¤è¤¯¤Ê¤¤°ì·²¤Î¼À´µ¤Ç¤Ï¡¤ÂÛ»ù´ü¤Ë¾É¾õ¤¬¿Ê¹Ô¤·½ÐÀ¸»þ¤Ë¤ÏÉÂÂÖ¤¬´°À®¤·¤Æ¤¤¤ë¡¥²¾¤Ë¼£ÎÅË¡¤¬¤¢¤Ã¤Æ¤â½ÐÀ¸¸å¤Ç¤Ï¤¹¤Ç¤Ë¼êÃÙ¤ì¤Ë¤Ê¤ë¤¿¤á¡¤ÂÛ»ù´ü¤«¤é¤Î¼£ÎŤ¬É¬ÍפȤµ¤ì¤ë¡¥

ÂÛ»ù¤Ë¼£ÎŤò¤ª¤³¤Ê¤¦¥á¥ê¥Ã¥È¤ÏÂ礭¤¤¡¥¤Ò¤È¤Ä¤á¤ËÂÛ»ù¤ÎÌȱַϤÏ̤ȯã¤Ç̤½Ï¤Ç¤¢¤ë¤¿¤á¡¤°Ûʪ¤Ë¤µ¤é¤µ¤ì¤Æ¤âÌȱֳØŪ´²ÍƤ¬³ÍÆÀ¤µ¤ì¤ë¤³¤È¤Ç¤¢¤ë¡¥¤¹¤Ê¤ï¤Á¾¤Î¸ÄÂΤ«¤é¤ÎÁÈ¿¥¤Î°Ü¿¢¤Ë¤¿¤¤¤·¤Æ¤âµñÀäÈ¿±þ¤ò¤ª¤³¤·¤Ë¤¯¤¤¡¥ÂÛÀ¸¤ÎÁᤤ»þ´ü¤Ç¤¢¤ì¤Ð°Ü¿¢ÊҽɼçÉ¡ÊGVHD¡Ë¤ÏȯÀ¸¤·¤Ê¤¤¤·¡¤¥Ò¥ÈÇò·ìµå¹³¸¶¡ÊHLA¡Ë¥¿¥¤¥Ô¥ó¥°¤Î°ìÃפâɬÍפʤ¤¡¥¤Õ¤¿¤Ä¤á¤Ï·ì±ÕǾ´ØÌ礬¤¸¤å¤¦¤Ö¤ó¤Ë´°À®¤·¤Æ¤¤¤Ê¤¤¤³¤È¤Ç¤¢¤ë¡¥¹ü·ÏÅý¼À´µ¤Ï°äÅÁ»ÒɤǤ¢¤ê¡¤¹üÆð¹ü·Ï¤Î¤ß¤Ê¤é¤ºÂ¾¤ÎÁ´¿È¤ÎÁÈ¿¥¡¤¤È¤¯¤ËÃæ¿õ¿À·Ð·Ï¤Ë¤â¾É¾õ¤¬½Ð¸½¤¹¤ë¤³¤È¤¬¤ª¤ª¤¤¤¬¡¤°Ü¿¢ºÙ˦¤ä¥¿¥ó¥Ñ¥¯¼Á¤Ï°ìÈ̤˷ì±ÕǾ´ØÌç¤òÄ̲á¤Ç¤­¤Ê¤¤¤¿¤áÃæ¿õ¿À·Ð¾É¾õ¤Ë¤¿¤¤¤·¤Æ¤ÏÍ­¸ú¤Ç¤Ï¤Ê¤¤¡¥¤·¤«¤·½ÐÀ¸Á°¤Ï·ì±ÕǾ´ØÌ礬̤½Ï¤Ç°Ü¹ÔÀ­¤¬¤ß¤È¤á¤é¤ì¡¤ÂÛ»ù´ü¤Î¼£ÎŤˤè¤Ã¤Æ¤è¤êÃæ¿õ¿À·Ð·Ï¤Ø¤Î¸ú²Ì¤â´üÂԤǤ­¤ë¡¥ºÇ¸å¤Ë¡¤°Ü¿¢¤µ¤ì¤¿´´ºÙ˦¤ËŬ¤·¤¿¿·¤·¤¤¥¹¥Ú¡¼¥¹¤È´Ä¶­¤¬È÷¤ï¤Ã¤Æ¤¤¤ë¤³¤È¤¬¤¢¤ë¡¥°Ü¿¢ºÙ˦¤äÁÈ¿¥¤¬À¸Ã夹¤ë¥¹¥Ú¡¼¥¹¤¬Â¸ºß¤·¡¤Áý¿£¤ËŬ¤·¤¿´Ä¶­¤Ç¤¢¤ë¤È¹Í¤¨¤é¤ì¤ë¡¥

¡¡

 ¹ÚÁÇÊä½¼ÎÅË¡¤Ë¤Ä¤¤¤Æ

ÀèÅ·À­¤Îñ°ì¹ÚÁǷ绤ˤè¤ëÉÂÂÖ¤ò¼¨¤¹¼À´µ¤Ë¤¿¤¤¤·¤Æ¤Ï¡¤¸½ºß¤Î°å³Ø¿å½à¤Ç¤ÏºÇ¤â¸½¼ÂŪ¤Ç¤«¤ÄÍ­¸ú¤È¹Í¤¨¤é¤ì¤Æ¤¤¤ë¼£ÎÅË¡¤Ç¤¢¤ë¡¥Âå¼ÕÀ­¹ü¼À´µ¤È¤è¤Ð¤ì¤ë°ì·²¤Î¼À´µ¤Ø¤ÎÍ­¸úÀ­¤¬´üÂԤǤ­¤ë¡¥¤¿¤È¤¨¤Ð¥à¥³Â¿Åü¾É¡ÊMPS¡Ë¤Î³Æ·¿¤Ë¤¿¤¤¤¹¤ë¹ÚÁÇÊä½¼ÎÅË¡¤Ï¤â¤Ã¤È¤â¸¦µæ¤µ¤ì¤Æ¤¤¤Æ¡¤¹ñÆâ¤Ë¤ª¤¤¤Æ¤ÏI·¿¡ÊHurler¾É¸õ·²¤ÈScheie¾É¸õ·²¡Ë¡¤II·¿¡ÊHunter¾É¸õ·²¡Ë¤ª¤è¤ÓVI·¿¡ÊMarouteaux-Lamy¾É¸õ·²¡Ë¤Î¼£ÎźޤÎÀ½Â¤ÈÎÇ䤬¾µÇ§¤µ¤ì¤Æ¤¤¤ë¡¥¤¿¤À¤·MPS¤Î¤ª¤ª¤¯¤¬¡¤¹ü·ÏÅý¼À´µ¤È°Û¤Ê¤ê½ÐÀ¸¸å¤Ë¾É¾õ¤¬¿Ê¹Ô¤¹¤ë¤â¤Î¤Ç¤¢¤ë¡¥

ÂÛ»ù´ü¤Î¹ÚÁÇÊä½¼ÎÅË¡¤¬´üÂÔ¤µ¤ì¤Æ¤¤¤ë¤Î¤ÏÄã¥Õ¥©¥¹¥Õ¥¡¥¿¡¼¥¼¾É¡Êhypophosphatasia; HPP¡Ë¤Ç¤¢¤ë¡¥HPP¤ÏÁÈ¿¥ÈóÆðÛŪ¥¢¥ë¥«¥ê¥Õ¥©¥¹¥Õ¥¡¥¿¡¼¥¼¡Êtissue-nonspecific isozyme of alkaline phosphatase; TNSALP¡Ë¤Î·ç»¤¬¸¶°ø¤Ç¤¯¤ëÉÂÍͤξɾõ¤ò¤­¤¿¤¹ÀèÅ·¼À´µ¤Ç¤¢¤ë¡¥¹ü²½ÉÔÁ´¡¤¥ê¥ó»À¤ä¥«¥ë¥·¥¦¥à¤ÎÄ´Àá¾ã³²¤òÆÃħ¤È¤·¡¤¹üÇ˲õ¤äÊÑ·Á¡¤½ÅÆƤʶÚÎÏÄã²¼¡¤¤±¤¤¤ì¤óȯºî¡¤¿Õµ¡Ç½¾ã³²¤ª¤è¤Ó¸ÆµÛÉÔÁ´¤Ê¤ÉÊ£¿ô¤Î½ÅÍס´ï¤Î¿Ê¹ÔÀ­¾ã³²¤Ë¤¤¤¿¤ë¡¥¸½ºß¡¤¹ü¤Ø°Ü¹Ô¤·¤ä¤¹¤¯²þÎɤµ¤ì¤¿¥ê¥³¥ó¥Ó¥Ê¥ó¥ÈALPÀ½ºÞ¡ÊENB-0040¤Þ¤¿¤Ï¥¢¥¹¥Õ¥©¥¿¡¼¥¼¥¢¥ë¥Õ¥¡¡Ë(2)¤Ë¤è¤ë¹ÚÁÇÊä½¼ÎÅË¡¤Î¹ñºÝ¼£¸³¤¬¿Ê¹Ô¤·¤Æ¤¤¤Æ¡¤¹ñÆâ¤Ç¤âÂçºåÂç³Ø¡¦Âç±à·Ã°ì¤é¤òÃæ¿´¤Ë¤Ï¤¸¤Þ¤Ã¤Æ¤¤¤ë¡¥

HPP¤ÏÎ×¾²Åª¡¤°äÅÁŪ¤Ë°Û¼ÁÀ­¤¬¤¿¤«¤¯¡¤¹ñºÝʬÎà¤Ç¤Ï½Å¾ÉÅ٤ˤâ¤È¤Å¤¤¤Æ¼þ»º´üÃ׻෿¡¤Æý»ù·¿¡¤¾®»ù·¿¡¤À®¿Í·¿¤Ê¤É¤ËʬÎव¤ì¤Æ¤¤¤ë¡¥ÆäËÆüËܤˤª¤ª¤¤¼þ»º´üÃ׻෿¤Ç¤Ï¡¤ÂÛ»ù´ü¤Ë¾É¾õ¤¬½Ð¸½¿Ê¹Ô¤·¡¤¤·¤Ð¤·¤Ð»à»º¤Ê¤¤¤·¤Ï½ÐÀ¸Ä¾¸å¤Ë»àË´¤È¤Ê¤ë¤«¡¤½ÐÀ¸¤·¤¿¾ì¹ç¤Ç¤â¤ª¤â¤¤¸ÆµÛµ¡Ç½ÉÔÁ´¤ò¤È¤â¤Ê¤¦¤³¤È¤¬°ìÈÌŪ¤Ç¤¢¤ë¡¥¤³¤Î¤è¤¦¤Ë½ÐÀ¸»þ¤Ë¤Ï¤¹¤Ç¤ËÉÂÂÖ¤¬´°À®¤·¤Æ¤¤¤ë¼þ»º´üÃ׻෿¤Ë½½Ê¬¤Ê¼£ÎŸú²Ì¤òÆÀ¤ë¤¿¤á¤Ë¤Ï¡¤ÂÛ»ù´ü¤Ë¤¹¤Ç¤Ë²ðÆþ¤¹¤ëɬÍפ¬¤¢¤ë¡¥ÂÛ»ù¼£ÎŤ¬¤Ä¤è¤¯µá¤á¤é¤ì¤ë¤æ¤¨¤ó¤Ç¤¢¤ë¡¥

2012ǯ¤ÎNew England Journal of Medicine¤Ë11Îã¤Î½Å¾É¤ÎÄã¥Õ¥©¥¹¥Õ¥¡¥¿¡¼¥¼¾É¤ËÂФ¹¤ë¹ÚÁÇÊä½¼ÎÅË¡¤Î¸ú²Ì¤Ë¤Ä¤¤¤ÆÊó¹ð¤µ¤ì¤¿(3)¡¥¼þ»º´ü·¿¤¬5Î㡤Æý»ù·¿¤¬6Îã¤Ç¤¢¤Ã¤¿¡¥¤½¤Î¤Ê¤«¤Ë¤ÏºÇ½Å¾É·¿¤Ç¡¤½ÐÀ¸¸åÁá´ü¤«¤é¥ê¥³¥ó¥Ó¥Ê¥ó¥ÈALP¤ÎÅêÍ¿¤¬¤Ï¤¸¤Þ¤ê·àŪ¤Ê¸ú²Ì¤ò¤¢¤²¤Æ¤¤¤ëÎã¤â¤¢¤ê¡¤½ÐÀ¸Á°¤«¤é¤Î¹ÚÁÇÊä½¼¤¬²Äǽ¤È¤Ê¤ì¤Ð¤µ¤é¤Ê¤ëͽ¸å²þÁ±¤¬´üÂԤǤ­¤½¤¦¤Ç¤¢¤ë¡¥¤â¤Á¤í¤óÂÛ»ù¤Ë¥ê¥³¥ó¥Ó¥Ê¥ó¥ÈALP¤òÅêÍ¿¤¹¤ë¤¿¤á¤Ë¤Ï¡¤µ»½ÑŪ¤Ë¤Ï¤¢¤Þ¤êÌäÂê¤Ê¤¤¤¬¡¤ÎÑÍýŪ¤Ë²ò·è¤·¤Ê¤±¤ì¤Ð¤Ê¤é¤Ê¤¤¥Ï¡¼¥É¥ë¤¬¤¢¤ë¡¥¤Þ¤º¤Ï½ÐÀ¸¸å¤Î°ìÈÌŪ¤Ê¹ÚÁÇÊä½¼ÎÅË¡¤¬Î×¾²Åª¤Ë³ÎΩ¤·¡¤¹ñÆâ¤Çǧ²Ä¤µ¤ì¤Æ¤«¤é¤Î¸¡Æ¤¤Ë¤Ê¤ë¤À¤í¤¦¡¥

¡¡

 ºÆÀ¸°å³Ø¤ò±þÍѤ·¤¿ÂÛ»ù¼£ÎÅ

ºÆÀ¸°å³Ø¤Ï¸½ºß¤â¤Ã¤È¤âÇ®¤¤Ê¬Ìî¤Ç¤¢¤ê¡¤Â¿Ç½À­´´ºÙ˦¡ÊESºÙ˦¤äiPSºÙ˦¡Ë¤ÎÍøÍѤ伫¸ÊÁÈ¿¥Í¶Æ³¡¤¥¯¥í¡¼¥óºîÀ½¡¤Â¡´ïÇÝÍܤʤɤˤĤ¤¤Æ¤Î¸¦µæ¤¬Æü¡¹À¤´Ö¤ò¤Ë¤®¤ï¤»¤Æ¤¤¤ë¡¥¤·¤«¤·ÂÛ»ù°åÎŤˤª¤¤¤ÆºÆÀ¸°å³Ø¤Ï¤É¤Î¤è¤¦¤Ë°ÌÃ֤Ť±¤é¤ì¤ë¤«¡¥¤½¤â¤½¤âºÆÀ¸°å³Ø¤È¤Ï¡¤¡ÖÂÛ»ù´ü¤Ë¤·¤«·ÁÀ®¤µ¤ì¤Ê¤¤¿ÍÂΤÎÁÈ¿¥¤¬·ç»¤·¤¿¾ì¹ç¤Ë¤½¤Îµ¡Ç½¤ò²óÉü¤µ¤»¤ë°å³ØʬÌî¡×¤È¤¤¤ï¤ì¤ë¤³¤È¤¬¤¢¤ê¡¤ÂÛ»ùÁÈ¿¥¤äçÁÂӷ졤ÍñË켫ÂΤ¬ºÆÀ¸°åÎŤΥ꥽¡¼¥¹¤È¤·¤ÆÃíÌܤµ¤ì¤Æ¤¤¤ë¡¥ÂÛ»ù´ü¤ÎºÙ˦¤äÁÈ¿¥¤ÎºÆÀ¸Ç½ÎϤϹ⤤¤Î¤Ç¡¤ÂÛ»ù¼«ÂΤˤ¿¤¤¤¹¤ëºÆÀ¸°åÎż«ÂΤ¬¿ÆÏÂÀ­¤¬Â礭¤¤¤È¤¤¤¨¤ë¡¥¡¡ÂÛ»ù¤Ë¤¿¤¤¤¹¤ëºÆÀ¸°åÎŤˤª¤¤¤Æ¤Ï¡¤´´ºÙ˦°Ü¿¢stem cell transplantation¤ÈÁÈ¿¥¹©³Øtissue engineering¤Î£²¤Ä¤Ë¤ï¤«¤ì¤ë¡¥´´ºÙ˦°Ü¿¢¤È¤ÏESºÙ˦¤äiPSºÙ˦¡¤¤¢¤ë¤¤¤ÏÂÎÀ­´´ºÙ˦¤ò»ÒµÜÆâÂÛ»ù¤ËÅêÍ¿¤·¡¤Àµ¾ï¡´ï¤äÁÈ¿¥ºÙ˦¤Ø¤Îʬ²½Í¶Æ³¤ò¤ª¤³¤Ê¤¦¼£ÎŤǤ¢¤ë¡¥¤Þ¤¿¡¤ÁÈ¿¥¹©³Ø¤È¤ÏÇ¥¿±Ãæ¤ËÂÛ»ù¼«¿È¤ä¤½¤ì°Ê³°¤«¤éºÙ˦¤äÁÈ¿¥¤òºÎ¼è¤·¡¤ÁÈ¿¥¹©³ØŪ¼êË¡¤Ç¤Ä¤¯¤Ã¤¿ÁÈ¿¥¹½Â¤Êª¤òÂÛ»ù¼ê½Ñ¤ä¿·À¸»ù³°²Ê¼ê½Ñ¤Ë±þÍѤ¹¤ëµ»½Ñ¤Ç¤¢¤ë¡¥

ºÆÀ¸°åÎżÂÍѲ½¤Î°ì´Ä¤È¤·¤Æ¡¤HPP¤ÎÆýÍÄ»ù¤Ë¤¿¤¤¤¹¤ë¹ü¿ñ°Ü¿¢Ê»ÍÑƱ¼ï´ÖÍÕ·Ï´´ºÙ˦°Ü¿¢¤¬Å纬Âç³Ø¤ÎÃÝë·ò¤é¤Ë¤è¤Ã¤Æ¸¦µæ»ö¶È¤È¤·¤Æ¹Ô¤ï¤ì¤Æ¤¤¤ë(4)¡¥¤â¤È¤â¤ÈÂÛ»ù°å³Ø¤ÎʬÌî¤Ë¤Ï»ÒµÜÆâ´´ºÙ˦°Ü¿¢¼£ÎÅ¡Êin utero stem cell transplantation; IUSCT¡Ë¤È¤¤¤¦³µÇ°¤¬¤¢¤Ã¤Æ¡¤²áµî25ǯ´Ö¤Ë50Îã°Ê¾å¤ÎÎ×¾²±þÍÑÎ㤬Êó¹ð¤µ¤ì¤Æ¤¤¤ë(5)¡¥ÀèÅ·À­¤Î·ì±Õ¼À´µ¤äÂå¼ÕÀ­¼À´µ¤¬Ãæ¿´¤Ç¤¢¤ê¡¤½Å¾ÉÊ£¹çÌȱÖÉÔÁ´¾É¡Êsevere combined immunodeficiency; SCID¡Ë¤Ê¤É°ìÉô¤ÎÌȱÖÉÔÁ´¾É¤Ë¤Ï¸ú²Ì¤¬Ç§¤á¤é¤ì¤Æ¤¤¤ë¡¥¥É¥Ê¡¼ºÙ˦¤ÏÉã¿Æ¤Î¹ü¿ñ´´ºÙ˦¤äÀµ¾ïÃæÀäÂÛ»ù¤Î´´ºÙ˦¤¬»È¤ï¤ì¤ë¡¥¹ü·ÏÅý¼À´µ¤ËÂФ¹¤ëIUSCT¤Ë¤Ä¤¤¤Æ¤Ï¡¤¹ü·ÁÀ®ÉÔÁ´¾ÉÂÛ»ù¤Ë¤¿¤¤¤¹¤ëÉã¿Æ¤Î¹ü¿ñ°Ü¿¢¤Ë¤Ä¤¤¤Æ3¾ÉÎã¤ÎÊó¹ð(6)(7)¤¬¤¢¤ê¡¤°ì±þ¡¤ÂÛ»ù¼£ÎŸå¤Ë¾É¾õ¤Î´²²ò¤ò¤ß¤È¤á¤¿¤³¤È¤¬Êó¹ð¤µ¤ì¤Æ¤¤¤ë¡¥¶áǯ¤ÏÍÓ¿åÃæ¤Î´´ºÙ˦¡ÊÍÓ¿å´´ºÙ˦amniotic fluid-derived stem cell¡Ë¤Î¸ºß¤¬ÃíÌܤµ¤ì¡¤ÀèÅ·°Û¾ï¤Î¼£ÎŤÎcell source¤È¤·¤Æ´üÂÔ¤µ¤ì¤Æ¤¤¤ë(8)¡¥

ÂÛ»ùÁÈ¿¥¹©³Ø¤Ë¤ª¤¤¤Æ¤Ï¡¤ÀÔ¿ñ¿ñËìá¸ý¿°Îö¡¤µðÂç¼ðáç¤Î¼ê½Ñ¤Ë¤ª¤±¤ëÈéÉæ·ç»Éô¤ÎÁÈ¿¥¹½Â¤Êª¤Ë¤è¤ëÊĺ¿¤Ê¤É¤¬»î¤ß¤é¤ì¤Æ¤¤¤ë¤¬¡¤¹ü·ÏÅý¼À´µ¤òľÀÜǰƬ¤Ë¤ª¤¤¤¿¤â¤Î¤Ï¤¤¤Þ¤Î¤È¤³¤í¤Ê¤¤¡¥µþÂç¤ÎºÊÌÚÈϹԤé¤Ï¡¤¥Ò¥È¤ÎÈéÉæºÙ˦¤Ë°äÅÁ»Ò¤òƳÆþ¤·¤Æ¡¤iPSºÙ˦¤ò·Ð¤º¤ËÆð¹üºÙ˦¤ËͶƳ¤¹¤ë¤³¤È¤ËÀ®¸ù¤·¤¿¡Ê¡Ö¥À¥¤¥ì¥¯¥È¡¦¥ê¥×¥í¥°¥é¥ß¥ó¥°¡×¡Ë(9)¡¥¹ü·ÏÅý¼À´µ¤Î»ù¤ÎÈéÉæ¤ò¤Ä¤«¤Ã¤ÆÉÂŪÆð¹üÁÈ¿¥¤òºîÀ®¤¹¤ë¤³¤È¤â²Äǽ¤Ç¤¢¤ê¡¤¤³¤ì¤â°ì¼ï¤ÎÁÈ¿¥¹©³Ø¤È¤¤¤¨¤ë¡¥¤½¤Î¥â¥Ç¥ë¤ò¤â¤Á¤¤¤Æ¼£ÎÅÌô¤Î³«È¯¤¬´üÂÔ¤µ¤ì¤Æ¤ª¤ê¡¤¤Þ¤¿¾­ÍèŪ¤Ë¤Ï°Û¾ïÆð¹ü¤ÎľÀܼ£ÎŤˤâ±þÍѤǤ­¤ë¤«¤â¤·¤ì¤Ê¤¤¡¥

¡¡

 °äÅÁ»Ò¼£ÎÅ

¹ü·ÏÅý¼À´µ¤Ï´ðËÜŪ¤Ë°äÅÁ»Ò¼À´µ¤Ç¤¢¤ë¤¿¤á¡¤°äÅÁ»Ò¼£ÎŤ¬¿¿¤Î°ÕÌ£¤Ç¤Îº¬ËÜŪ¤Ê¼£ÎŤȤʤ뤬¡¤¥Ò¥ÈÂÛ»ù¤Ë°äÅÁ»Ò¼£ÎŤ¬¤Ê¤µ¤ì¤¿Êó¹ð¤Ï¤Þ¤À¤Ê¤¤¡¥°äÅÁ»ÒƳÆþ¤Î¤¿¤á¤Î¥¦¥¤¥ë¥¹¥Ù¥¯¥¿¡¼¤Ë¤è¤ë¥ê¥¹¥¯¤¬ÌÀ¤é¤«¤Ç¤¢¤ë¤³¤È¤È¡¤¸½»þÅÀ¤Ç¤ÏÀ¸¿£ºÙ˦¤Î°äÅÁ»Ò²þÊѤϥ¬¥¤¥É¥é¥¤¥ó¤Ç¶Ø¤¸¤é¤ì¤Æ¤¤¤ë¤¬¡¤ÂÛ»ù¤Ë°äÅÁ»ÒƳÆþ¤ò¤ª¤³¤Ê¤¦¤È¤¢¤ë°ìÄê¤Î³ä¹ç¤ÇÀ¸¿£ºÙ˦¤Ë¤â±Æ¶Á¤¬¤¢¤ë¤³¤È¤¬¤ï¤«¤Ã¤Æ¤¤¤ë¤¿¤á¤Ç¤¢¤ë¡¥¤·¤«¤·°ÂÁ´¤Ê°äÅÁ»ÒƳÆþË¡¤¬³«È¯¤µ¤ì¡¤¤³¤¦¤¤¤Ã¤¿¾ãÊɤ¬¤Ê¤¯¤Ê¤ì¤Ð¡¤°äÅÁ»ÒÉ¤Τª¤ª¤¯¤Ç¤³¤Î¼£ÎŤ¬Å¬±þ¤È¤Ê¤ë¤ÈͽÁÛ¤µ¤ì¤ë¡¥

ưʪ¼Â¸³¤Ë¤ª¤±¤ë»ÒµÜÆâ¤Ç¤Î°äÅÁ»Ò¼£ÎŤΤ¤¤¯¤Ä¤«¤ÎÊó¹ð¤¬¤¢¤ë¡¥ÆüËÜ°åÂç¤ÎÅçÅÄδ¤é¤Î¥°¥ë¡¼¥×¤Ï¡¤¥Ò¥ÈHPP½Å¾É·¿¤Ë»÷¤Æ¤¤¤ëHPP¥â¥Ç¥ëÇ¥¿±¥Þ¥¦¥¹¤òÍѤ¤¡¤ÂÛÎð15Æü¤ËÂۻƤÎÊ¢¹ÐÆâ¤Ë¹ü¤ò¥¿¡¼¥²¥Ã¥È¤È¤·¤¿TNALPȯ¸½¤Î¥¢¥Ç¥Î¿ïȼ¥¦¥¤¥ë¥¹9¡ÊAAV9¡Ë¤òÃíÆþ¤·¤¿(10)¡¥½èÃÖ¤ò¤ª¤³¤Ê¤Ã¤¿¥Þ¥¦¥¹¿·À¸»Æ¤Ï¥³¥ó¥È¥í¡¼¥ë·²¤È¤¯¤é¤Ù¹â¤¤À¸Â¸Î¨¤ÈXÀþ½ê¸«¤Î²þÁ±¤Ê¤É¤òǧ¤á¡¤Âۻƴü¤Î°äÅÁ»Ò¼£ÎŤι⤤¸ú²Ì¤ò¼¨¤·¤Æ¤¤¤ë¡¥

ÂÛ»ù°äÅÁ»Ò¼£ÎŤϰäÅÁ»ÒɤÎȯ¾É¤ä¿Ê¹Ô¤ÎͽËɤȤ·¤Æ¤ª¤ª¤­¤Ê´üÂÔ¤¬¤è¤»¤é¤ì¤Æ¤¤¤ë¤¬¡¤¤¿¤À¤·¤Þ¤À¼Â¸³ÅªÃʳ¬¤Ë¤¢¤ë¡¥ÁÞÆþÆÍÁ³ÊÑ°Û¤ÎÌäÂê¤ä¡¤Àµ¾ïÁÈ¿¥¤Ø¤Î±Æ¶Á¤Ê¤É¤Ï¤Ã¤­¤ê¤·¤Ê¤¤ÌäÂ꤬»Ä¤Ã¤Æ¤¤¤ë¤³¤È¤ä¡¤°äÅÁ»Ò¼£ÎŤä¥Ò¥È¥²¥Î¥à¤Î²þÊѤʤɤˤĤ¤¤ÆÀ¸Ì¿ÎÑÍýŪ¤ÊµÄÏÀ¤¬¤µ¤é¤ËɬÍפǤ¢¤ë¤³¤È¤Ê¤É²ÝÂê¤Ï¿¤¤¡¥¤½¤ì¤Ë¤â¤«¤«¤ï¤é¤ºÂÛ»ù¤Î°äÅÁ»Ò¼£ÎŤˤĤ¤¤Æ¤ÏÂ礭¤Ê²ÄǽÀ­¤¬¤¢¤ê¡¤¤³¤ì¤é¤Î²ÝÂê¤ò²ò·è¤·¤Æ¤¤¤¯¤³¤È¤Ë¤è¤Ã¤Æ¿¤¯¤Î¹ü·ÏÅý¼À´µ¤ÎÂÛ»ù¼£ÎŤ¬²Äǽ¤È¤Ê¤Ã¤Æ¤¤¤¯¤³¤È¤À¤í¤¦¡¥

¡¡

 ¤ª¤ï¤ê¤Ë

¹ü·ÏÅý¼À´µ¤ÎÂÛ»ù¼£ÎŤȤ·¤Æ¸½ºß¹Í¤¨¤é¤ì¤Æ¤¤¤ë¤Î¤Ï¡¤­¡¹ÚÁÇÊä½¼ÎÅË¡¡¤­¢ºÆÀ¸°åÎŤȤ·¤Æ¤Î´´ºÙ˦°Ü¿¢¡¤­£°äÅÁ»Ò¼£ÎŤΣ³¤Ä¤Ç¤¢¤ë¡¥¹ü·ÏÅý¼À´µ¤ÎÂÛ»ù¼£ÎŤȤ·¤Æ¤Ï»ÒµÜÆâ´´ºÙ˦°Ü¿¢¤¬²¿Î㤫¤ª¤³¤Ê¤ï¤ì¤¿Êó¹ð¤¬¤¢¤ë¤Î¤ß¤À¤¬¡¤¸½»þÅÀ¤ÇÍ­¸úÀ­¤È¼Â¸½À­¤¬¤â¤Ã¤È¤â´üÂԤǤ­¤ë¤Î¤Ï¹ÚÁÇÊä½¼ÎÅË¡¤Ç¤¢¤í¤¦¡¥¹ü·ÏÅý¼À´µ¤ÎÂÛ»ù¼£ÎŤˤĤ¤¤Æ¤Ï¤½¤Î°ÂÁ´À­¤ÈÎÑÍýŪ¤ÊÌäÂê¤Ë¤è¤ê¤¤¤º¤ì¤â¤Þ¤À¸¦µæÃʳ¬¤Ç¤¢¤ë¡¥¤·¤«¤·½ÐÀ¸»þ¤Ë¤Ï¤¹¤Ç¤ËÉÂÂÖ¤¬´°À®¤·¤Æ¤¤¤ë½Å¾ÉÎã¤ò¼£ÎŤ·¤Æ¤¤¤¯¤¿¤á¤Ë¤Ï¡¤ÁᤤÃʳ¬¤Ç¤Î¼£Îų«»Ï¤¬µá¤á¤é¤ì¤Æ¤ª¤ê¡¤¤³¤ì¤é¤ÎÂÛ»ù¼£ÎŤˤ¿¤¤¤¹¤ë´üÂÔ¤ÏÂ礭¤¤¤È¤¤¤¨¤ë¡¥

¡¡

 Ê¸¡¡¸¥

(1) ÂÛ»ù¹ü·ÏÅý¼À´µ¥Õ¥©¡¼¥é¥à¥Û¡¼¥à¥Ú¡¼¥¸¡§http://plaza.umin.ac.jp/~fskel/cgi-bin/wiki/wiki.cgi?page=FrontPage

(2) Millan JL, Narisawa S, Lemire I, et al: Enzyme replacement therapy for murine hypophosphatasia. J Bone Mener Res 2008;23:777-787

(3) Whyte MP, Greenberg CR, Salman NJ, et al: Enzyme-replacement therapy in life-threatening Hypophosphatasia. New Engl J Med 2012;366:904-913

(4) Taketani T, Kanai R, Abe M, et al: Therapy-related Ph+ leukemia after both bone marrow and mesenchymal stem cell transplantation for hypophosphatasia. Pediatr Int 2013;55:e52-55

(5) Vrecenak JD, Flake AW: In utero hematopoietic cell transplantation – recent progress and the potential for clinical application. Cytotherapy 2013;15:525-535

(6) Le Blanc K, Gotherstom C, Ringden O, et al: Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation 2005;79:1607-1614

(7) Yamamoto M, Conget P, Allers C, et al: Intrauterine transfusion (IUT) of mesenchymal stem cells in two fetuses with severe fractures led to no postnatal fractures up to 1- and 2- years of age. Ultrasound Obstet Gynecol 2007;30:650

(8) Kunisaki SM: Congenital anomalies – treatment options based on amniotic fluid-derived stem cells. Organogenesis 2012;8:89-95

(9) Outani H, Okada M, Yamashita A, et al: Direct induction of chondrogenic cells from human dermal fibroblast culture by defined factors. PLoS ONE 2013;8(10): e77365. doi:10.1371/journal.pone.0077365

(10) Sugano H, Matsumoto T, Miyake K, et al: Successful gene therapy in utero for lethal murine hypophosphatasia. Hum Gene Ther 2012;23:399-406

--------------------------------------------------------------------

ÂÛ»ù¹ü·ÏÅý¼À´µ¥Õ¥©¡¼¥é¥à¥È¥Ã¥×¡¡¤Ë¤â¤É¤ë

ÂÛ»ù¼£ÎÅ¡¡¤Ë¤â¤É¤ë

¥Õ¥í¥ó¥È¥Ú¡¼¥¸¡¡¤Ë¤â¤É¤ë

¥«¥¦¥ó¥¿¡¡9149¡Ê2014ǯ8·î28Æü¤è¤ê¡Ë